Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.33 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 3/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9260380 | 1.00 | CHRM2 (0.50) | CHRM2CHRM5CHRM1CHRM3TSHR | |
| Hydrochloric Acid SCHEMBL9257066 | 0.98 | CHRM2 (0.49) | CHRM2CHRM5CHRM1CHRM3TSHR | |
| Hydrochloric Acid SCHEMBL9257070 | 0.98 | CHRM2 (0.49) | CHRM2CHRM5CHRM1CHRM3TSHR | |
| Hydrochloric Acid SCHEMBL194267 | 0.96 | CHRM2 (0.47) | CHRM2CHRM5CHRM1CHRM3TSHR | |
| SCHEMBL12043329 | 0.80 | CHRM3 (0.34) | CHRM2CHRM5CHRM1CHRM3TSHR | |
| SCHEMBL8734689 | 0.76 | — | — | |
| SCHEMBL9628635 | 0.76 | — | — | |
| SCHEMBL8734690 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL9265275 | 0.72 | CHRM3 (0.31) | CHRM3BLM | |
| Hydrochloric Acid SCHEMBL9265269 | 0.72 | CHRM3 (0.31) | CHRM3BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012170599-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-5391754-A | Oximination a tetrahydropyridin-3-aldehyde, alkylation with a halides, salt formation | ROUSSEL UCLAF (FR) | 1995-02-21 | — | — | US | disclosed |
| US-5231107-A | Compounds for treatment of Alzheimer*s disease or memory defects | ROUSSEL UCLAF (FR) | 1993-07-27 | — | — | US | disclosed |
| US-5219872-A | Treating Alzheimer*s disease, memory disorders | ROUSSEL UCLAF (FR) | 1993-06-15 | — | — | US | disclosed |
| EP-0308283-B1 | 1,2,5,6-TETRAHYDROPYRIDINE-3-CARBOXALDEHYDE OXIME DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AS PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS CONTAINING THEM | ROUSSEL-UCLAF (FR) | 1992-01-22 | — | — | EP | disclosed |
| US-4927837-A | TREATMENT OF ALZHEIMER'S DISEASE, SENILE DEMENTIA, OR MEMORY DISORDERS IN THE AGED | ROUSSEL UCLAF (FR) | 1990-05-22 | — | — | US | disclosed |
| US-4921868-A | Carbamate derivatives of the oxime of 1,2,5,6-tetrahydropyridin-3-carboxaldehyde, their use as medicaments and compositions containing them | ROUSSEL UCLAF (FR) | 1990-05-01 | — | — | US | disclosed |
| US-4902699-A | Oxime of 1, 2, 5, 6-tetrahydropyridine compounds their use as medicaments and the compositions containing them | ROUSSEL UCLAF (FR) | 1990-02-20 | — | — | US | disclosed |
| EP-0308283-A1 | 1,2,5,6-Tetrahydropyridine-3-carboxaldehyde oxime derivatives, process for their preparation, their use as pharmaceutical compounds and compositions containing them | ROUSSEL-UCLAF (FR) | 1989-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | CHRM2 15/4885CHRM5 16/4885CHRM1 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.